Quantisnow Logo
Dashboard

Theravance Biopharma to Participate in an Upcoming Investor Conference

$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $TBPH alert in real time by email

DUBLIN, March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).

Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To attend the fireside chat and schedule meetings with management, please contact your Jones representative or email Yuki Gonzalez, Vice President, Marketing & Corporate Access (ygonzalez@jonestrading.com).

A recording of the event will be available after the conference and may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. The recording will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:

investor.relations@theravance.com

650-808-4045

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302415277.html

SOURCE Theravance Biopharma, Inc.

Get the next $TBPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TBPH

DatePrice TargetRatingAnalyst
8/6/2024$15.00 → $10.00Outperform → Market Perform
Leerink Partners
4/12/2024$21.00Buy
BTIG Research
1/8/2024Outperform → In-line
Evercore ISI
5/23/2022$12.00Outperform
SVB Leerink
3/2/2022$10.00 → $11.00Underweight
Morgan Stanley
2/24/2022$8.00 → $12.00Buy
HC Wainwright & Co.
11/5/2021$7.00 → $12.00Underweight → Neutral
JP Morgan
9/16/2021$14.00 → $10.00Underweight
Morgan Stanley
More analyst ratings

$TBPH
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Theravance Biopharma to Participate in an Upcoming Investor Conference

    DUBLIN, March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To attend the fireside chat and schedule meetings with management, please contact your Jones representative or email Yuki Gonzalez, Vice President, Marketing & Corporate Access (ygonzalez@jonestrading.com). A recording

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

    DUBLIN, March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing nOH in patients with multiple system atrophy, which is currently ongoing.

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

    YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma2,3CYPRESS study on track to enroll final patient in the open label portion by mid-2025Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone, with cash receipt in February 2025DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial an

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TBPH
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TBPH
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TBPH
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TBPH
 SEC Filings

See more

$TBPH
 Leadership Updates

Live Leadership Updates

See more

  • Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

    Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors

    Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors

    DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TBPH
 Financials

Live finance-specific insights

See more

  • Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

    YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma2,3CYPRESS study on track to enroll final patient in the open label portion by mid-2025Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone, with cash receipt in February 2025DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial an

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

    DUBLIN, Ireland, Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's w

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

    Third quarter results highlight strong operational performance across key value drivers:YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241CYPRESS enrollment in-line with expectations, with timelines on trackTRELEGY net sales increased 17%, to $789 million, as reported by GSK:Q4 sales of at least ~$260 million needed to earn $25 million milestone2Q4 sales of at least ~$610 million needed to earn $50 million milestone2Board of Directors announces initiatives to unlock shareholder value and enhance corporate governanceDUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharm

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TBPH
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more